Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More

MENU

Study Examines Cardiopulmonary Risks of Surgery in Patients With Prostate, Kidney Cancer

September 11, 2021

Kevin Ginsburg, MD, lead author on the study and second-year fellow in the Urologic Oncology Fellowship Program at Fox ChaseKevin Ginsburg, MD, lead author on the study and second-year fellow in the Urologic Oncology Fellowship Program at Fox Chase

PHILADELPHIA (September 11, 2021)—In a recent study, Fox Chase Cancer Center researchers highlighted immediate cardiopulmonary risks associated with patients undergoing minimally invasive partial nephrectomy or prostatectomy for low-grade, low-stage disease. The study compared these risks with those associated with disease surveillance.

Researchers will present these findings during the virtual American Urologic Association 2021 Annual Meeting.

“The impetus of this project was that for both of these—prostate cancer and kidney cancer—for low-grade, low-stage disease, active surveillance has been established as a viable and reasonable oncological treatment,” said Kevin Ginsburg, MD, lead author on the study and second-year fellow in the Urologic Oncology Fellowship Program at Fox Chase.

“In debating treatment versus observation, part of that calculus is the downside of treatment. If a patient can safely undergo treatment, should they just undergo surgery and then not have to worry about watching their condition in the future?” added Ginsburg, who conducted the study with colleagues from the Division of Urology and Urologic Oncology at Fox Chase.

Researchers examined information from the American College of Surgeons National Surgical Quality Improvement Program database for patients undergoing minimally invasive prostatectomies and minimally invasive partial nephrectomies from 2015 to 2019. Cardiopulmonary events noted in the study included pneumonia, deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, cardiovascular arrest, and death.

“We found that of the nearly 65,000 patients that underwent minimally invasive prostatectomy or partial nephrectomy in this registry, around 2% of them had a cardiopulmonary event within 30 days, including 87 patients who unfortunately died within 30 days,” said Ginsburg.

In comparing these cardiopulmonary events with other postoperative outcomes like readmission and length of stay, patients who had these cardiopulmonary events were much more likely to be readmitted, have a longer stay, and have reoperations, Ginsburg said.

“If we think about it, the perioperative risks of surgery are immediate and around 2%. The oncological risks with not treating someone with surgery are typically delayed to five or 10 years down the line, which is a similar risk of around 2% or 3% of dying from a cancer like this,” said Ginsburg.

He added that findings gleaned from this study should be integrated into the shared decision-making process in patients for which active surveillance has been established as an oncologically safe option.

The study, “Understanding the Risks of Surgery in Urologic Patients with Low Risk Cancers: Quantifying Perioperative Cardiopulmonary Events Following Minimally Invasive Prostatectomy and Partial Nephrectomy,” was published in The Journal of Urology.

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

 

For more information, call 888-369-2427

Connect with Fox Chase